Clinical Lab Testing / Disease States

Cystatin C Estimates Kidney Function

Cystatin C Estimates Kidney FunctionStudies show that Cystatin C can be successfully used as a sensitive marker to monitor kidney function. Testing blood levels of cystatin C, (either solely or combined with creatinine measurement) highlights the correlation between kidney function and end-stage renal disease and death.

A multi-national study, incorporating over 90,000 participants from the USA, Europe and Australia allowed for the examination of cystatin C levels and its ability to measure kidney function.

Cystatin C levels were recorded either solely or in combination with creatinine to determine kidney function whilst recording participant cardiovascular related death rates and end-stage kidney disease.

Estimating kidney function is crucial to diagnosing and managing chronic kidney disease. However creatinine testing can miss the early signs of kidney function loss. Blood tests using the creatinine biomarker only highlight an issue once kidney function falls to 60 ml/min/1.73m, (meaning kidney disease is in chronic decline).

Findings reported in the Sept. 5 edition of the New England Journal of Medicine1, show that the risks associated with declining kidney function can be evaluated using a Cystatin C test when kidney function reaches 85 Ml/minute/1.73 m, much earlier than the threshold of chronic kidney disease.

Researchers note that Cystatin C has the added benefit of not being affected by muscle mass; meaning that less adjustment is needed for age and gender. Further to this, Cystatin C works similarly on both black and white patients meaning it is globally relevant.

Reference:

1.    Michael G. Shlipak, M.D., M.P.H., Kunihiro Matsushita, M.D., Ph.D., Johan Ärnlöv, M.D., Ph.D., Lesley A. Inker, M.D., Ronit Katz, D.Phil., Kevan R. Polkinghorne, F.R.A.C.P., M.Clin.Epi., Ph.D., Dietrich Rothenbacher, M.D., M.P.H., Mark J. Sarnak, M.D., Brad C. Astor, Ph.D., M.P.H., Josef Coresh, M.D., Ph.D., Andrew S. Levey, M.D., and Ron T. Gansevoort, M.D (2013) Cystatin C versus Creatinine in Determining Risk Based on Kidney Function. The New England Journal of Medicine.

LineThe Randox Research division offers two high quality Metabolic Syndrome arrays allowing for the simultaneous detection of biomarkers associated with metabolic syndrome. Randox’s unique Metabolic Syndrome II array for the simultaneous detection of Cystatin C, Adiponectin and C-reactive Protein (CRP). To see how Randox Research could aid your research view our Metabolic and Nutrition Research brochure.

Leave a Reply

Your email address will not be published. Required fields are marked *

*